Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017135
Chunk: 33

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 33
---
 the rules and regulations promulgated thereunder.

Stock dividends and stock splits.If we pay a stock dividend or otherwise make a distribution payable in Depositary Shares or Ordinary Shares, or any
other equity or equivalent securities, subdivide or combine outstanding Depositary Shares or Ordinary Shares, or reclassify Depositary
Shares, Ordinary Shares or any shares of our capital stock, the exercise price of each warrant will be adjusted by multiplying the then
exercise price by a fraction, the numerator of which shall be the number of Depositary Shares (excluding treasury shares, if any) outstanding
immediately before such event, and the denominator of which shall be the number of Depositary Shares outstanding immediately after such
event.

Rights Offerings; pro rata distributions.If we issue Ordinary Share equivalents or rights to purchase shares, warrants, securities or other property pro
rata to holders of Depositary Shares, a holder of a warrant will be entitled to acquire, subject to the beneficial ownership limitation
described above, such securities or property that such holder could have acquired if such holder had held the number of Depositary Shares
issuable upon complete exercise of the warrant immediately prior to the date a record is taken for such issuance. If we declare or make
any dividend or other distribution of assets or rights to acquire assets to holders of Depositary Shares or Ordinary Shares, a holder
of a warrant will be entitled to participate, subject to the beneficial ownership limitation, in such distribution to the same extent
that the holder would have participated therein if the holder had held the number of Depositary Shares issuable upon full exercise of
the warrant.

| 20 |

Fundamental Transaction.If we effect a fundamental transaction, including, among other things, a merger, sale of substantially all of our assets, tender
offer, exchange offer and other business combination transactions, then upon any subsequent exercise of a warrant, the holder thereof
shall have the right to receive, for each Ordinary Share represented by the Depositary Shares that would have been issuable upon such
exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of the successor’s or acquiring
corporation’s securities, if it is the surviving corporation, and any additional consideration receivable as a result of such fundamental
transaction by a holder of the number of Ordinary Shares represented by the Depositary Shares for which the warrant is exercisable immediately
prior to such fundamental transaction. In addition, with respect to the Series E Warrants and the December 2023 Underwriter Warrants,
in the